Clinical trial of L-Carnitine and valproic acid in spinal muscular atrophy type I

for the Project Cure SMA Investigator's Network

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: The aim of this study was to determine the safety and therapeutic potential of L-carnitine and valproic acid (VPA) in infants with spinal muscular atrophy (SMA). Methods: Our investigation was an open-label phase 2 multicenter trial of L-carnitine and VPA in infants with SMA type I with retrospective comparison to an untreated, matched cohort. Primary outcomes were: safety and adverse events; secondary outcomes were survival, time to death/>16 hours/day of ventilator support; motor outcomes; and maximum ulnar compound motor action potential amplitude. Results: A total of 245 AEs were observed in 35 of the 37 treated subjects (95%). Respiratory events accounted for 49% of all adverse events, resulting in 14 deaths. Survival was not significantly different between treated and untreated cohorts. Discussion: This trial provides evidence that, in infants with SMA type I, L-carnitine/VPA is ineffective at altering survival. The substantial proportion of infants reaching end-points within 6 months of enrollment underscores the urgent need for pre-symptomatic treatment in SMA type I. Muscle Nerve 57: 193–199, 2018.

Original languageEnglish (US)
Pages (from-to)193-199
Number of pages7
JournalMuscle and Nerve
Volume57
Issue number2
DOIs
StatePublished - Feb 1 2018

Keywords

  • L-carnitine
  • clinical trials
  • infants
  • natural history
  • spinal muscular atrophy type I
  • valproic acid

ASJC Scopus subject areas

  • Physiology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Physiology (medical)

Fingerprint Dive into the research topics of 'Clinical trial of L-Carnitine and valproic acid in spinal muscular atrophy type I'. Together they form a unique fingerprint.

Cite this